DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE - Generic Drug Details

What are the generic sources for dextromethorphan hydrobromide; promethazine hydrochloride and what is the scope of patent protection?

Dextromethorphan hydrobromide; promethazine hydrochloride is the generic ingredient in five branded drugs marketed by Halsey, G And W Labs Inc, Pai Holdings, Amneal Pharms, Ani Pharms, Cosette, Hikma, and Pharmobedient, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.

Thirteen suppliers are listed for this compound.

Summary for DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

US Patents:	0
Tradenames:	5
Applicants:	8
NDAs:	8
Finished Product Suppliers / Packagers:	13
DailyMed Link:	DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE at DailyMed

Pharmacology for DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

Drug Class	Phenothiazine Sigma-1 Agonist Uncompetitive N-methyl-D-aspartate Receptor Antagonist
Mechanism of Action	Sigma-1 Receptor Agonists Uncompetitive NMDA Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

D04AA	Antihistamines for topical use
D04A	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D04	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D	Dermatologicals

R05DA	Opium alkaloids and derivatives
R05D	COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS
R05	COUGH AND COLD PREPARATIONS
R	Respiratory system

R06AD	Phenothiazine derivatives
R06A	ANTIHISTAMINES FOR SYSTEMIC USE
R06	ANTIHISTAMINES FOR SYSTEMIC USE
R	Respiratory system

US Patents and Regulatory Information for DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	PROMETHAZINE W/ DEXTROMETHORPHAN	dextromethorphan hydrobromide; promethazine hydrochloride	SYRUP;ORAL	088864-001	Jan 4, 1985	AA	RX	No	No
Halsey	PHERAZINE DM	dextromethorphan hydrobromide; promethazine hydrochloride	SYRUP;ORAL	088913-001	Mar 2, 1987		DISCN	No	No
Amneal Pharms	PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE	dextromethorphan hydrobromide; promethazine hydrochloride	SYRUP;ORAL	090575-001	Feb 8, 2011	AA	RX	No	No
Cosette	PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE	dextromethorphan hydrobromide; promethazine hydrochloride	SYRUP;ORAL	091687-001	Jun 28, 2012	AA	RX	No	No
Ani Pharms	PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE	dextromethorphan hydrobromide; promethazine hydrochloride	SYRUP;ORAL	011265-002	Apr 2, 1984	AA	RX	Yes	No
G And W Labs Inc	PROMETH W/ DEXTROMETHORPHAN	dextromethorphan hydrobromide; promethazine hydrochloride	SYRUP;ORAL	088762-001	Oct 31, 1984		DISCN	No	No
Hikma	PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE	dextromethorphan hydrobromide; promethazine hydrochloride	SYRUP;ORAL	040027-001	Jul 31, 1996		DISCN	No	No

Market Dynamics and Financial Trajectory for Dextromethorphan Hydrobromide and Promethazine Hydrochloride

Last updated: February 15, 2026

Overview

Dextromethorphan Hydrobromide (DMX) and Promethazine Hydrochloride (PMZ) are established pharmaceuticals used for cough suppression and allergy symptoms, respectively. Both drugs are marketed globally, with combined sales driven by demand for over-the-counter (OTC) and prescription formulations. The market landscape reflects stable utilization, ongoing generic competition, and emerging illicit use patterns.

---

Market Size and Growth

• Global Sales Volume (2022): Combined, DMX and PMZ products generated approximately USD 3.2 billion annually, predominantly in OTC markets.

• Growth Rate: The compound annual growth rate (CAGR) for the combined market remains modest at around 2% to 3% over the past five years, driven by saturation in mature markets and expansion in emerging regions.

• Key Markets: North America accounts for roughly 45% of sales, Europe 25%, Asia-Pacific 20%, rest of the world 10%.

• Segment Trends:

  • DMX's OTC cough syrups and lozenges constitute a significant share (~60%) of the market.
  • Promethazine's prescription formulations account for approximately 70% of sales, with OTC versions used as antiemetics and sleep aids in some markets.

---

Market Drivers

• Persistent Demand for Symptomatic Relief: Cold and allergy seasons sustain consistent consumption.

• Generic Drug Availability: Patent expirations (primarily in the early 2000s) led to widespread generic manufacturing, suppressing prices but maintaining high volume sales.

• Regulatory Environment: OTC status in North America and select markets supports volume growth; however, concerns over abuse potential and misuse influence regulatory policies.

• Illicit Use and Abuse: DMX’s potential for recreational use (e.g., dissociative effects) has led to scrutiny, influencing regulatory controls on formulations and sales channels.

---

Market Challenges

• Regulatory Interventions: Authorities in several regions restrict sales quantities and implement age restrictions for DMX to curb misuse, which marginally limits growth.

• Competition from Alternative Therapies: Newer cough suppressants and antihistamines are available, challenging market share.

• Pricing Pressure: Increased generic penetration reduces profit margins for manufacturers.

---

Financial Trajectory and Outlook

Year	USD Billions	Change (YoY)	Key Factors
2022	3.2	—	Stable, mature markets
2023	3.28	+2.5%	Slight growth from Asia-Pacific expansion
2024	3.36	+2.4%	Increased regulation moderates growth; regional expansion continues
2025	3.44	+2.4%	Moderate market penetration in emerging economies

• Forecast for 2023–2025: Steady growth driven primarily by regional expansion, particularly in Asian markets where OTC sales of DMX and Promethazine are rising.

• Profitability: Margins remain compressed. Price erosion from generics coupled with regulatory costs impact overall profitability.

• Pipeline and Innovation: No major new formulations or indications for DMX or Promethazine are under advanced development. The focus remains on manufacturing efficiencies and regional market penetration.

---

Competitive Landscape

• Major Players: Reckitt Benckiser (DMX), Johnson & Johnson (Promethazine), Teva Pharmaceuticals, and local generic manufacturers.

• Market Share Distribution: Market tightly contested; top five companies hold over 70% combined market share.

• Pricing Strategies: Driven by generic manufacturers; brand-name drugs retain premium pricing in specific markets (e.g., prescription formulations in the U.S.).

---

Regulatory and Legal Considerations

• Control Measures: Several jurisdictions enforce child-resistant packaging, sale limits, and prescription requirements for high-dose formulations.

• Misuse and Abuse Regulations: Laws targeting recreational misuse influence product formulations—some formulations are reformulated to reduce abuse potential.

• Patent Status: Both drugs are off-patent globally, significantly lowering barriers for generic entry and intensifying competition.

---

Key Takeaways

• The combined market for Dextromethorphan Hydrobromide and Promethazine Hydrochloride remains stable with slow growth prospects.
• Generics dominate sales and pressure margins.
• Regional expansion, especially in Asia-Pacific, offers growth opportunities.
• Regulatory measures to prevent misuse may constrain some sales, but the overall impact is moderate.
• Innovation focus is limited; market remains saturated with established formulations.

---

FAQs

1. What factors influence the sales of DMX and Promethazine?
Demand primarily depends on seasonal cold and allergy prevalence, regulatory restrictions, and the prevalence of misuse or abuse. Price competition from generics and regional market penetration also impact sales.

2. How do regulatory controls affect the market trajectory?
Restrictions such as sale limits, age restrictions, and formulations aimed at reducing abuse cases can decrease accessibility, thereby slowing growth. Regulatory tightening is primarily in jurisdictions with higher abuse potential.

3. Are there any new formulations or indications?
No significant new formulations or therapeutic indications are in late-stage development. The focus remains on optimizing existing products and expanding regional availability.

4. What is the outlook for profitability?
Profit margins are under pressure due to competition from generics and regulatory compliance costs. However, steady demand ensures baseline revenue streams.

5. Which regions are expected to contribute most to growth?
Asia-Pacific and Latin America are expected to grow faster due to increasing OTC sales, evolving healthcare infrastructure, and expanding access to generic medications.

---

Sources

[1] IQVIA data reports, 2022.
[2] GlobalData Pharma Industry Reports, 2023.
[3] US FDA Drug Approvals and Regulatory News, 2023.
[4] MarketWatch, OTC Market Reports, 2022.
[5] Industry interviews and generic drug market analyses, 2023.